Foster's syndrome - Symptoms, Causes, Treatment & Prevention

```html

Overview

Foster Kennedy syndrome (FKS) is a rare neuro‑ophthalmic disorder characterized by a distinctive combination of optic nerve atrophy in one eye and papilledema (swelling of the optic disc) in the other eye, usually caused by a frontal‑lobe mass that compresses the optic nerve on the side of the tumor while increasing intracranial pressure overall.

• Who it affects: Primarily adults aged 30‑60 years; slight male predominance (≈ 55 %). Most cases are associated with primary brain tumors such as olfactory groove meningiomas.
• Prevalence: Exact incidence is unknown because it is so rare, but case series from tertiary neuro‑ophthalmology centers estimate < 1 case per 10 000 neuro‑ophthalmic patients.

Understanding FKS is crucial because early detection often leads to timely tumor removal, preventing permanent visual loss and other serious complications.

Symptoms

The symptom profile reflects two opposing processes—optic nerve compression on the tumor side and generalized raised intracranial pressure (ICP). Common findings include:

• Unilateral optic atrophy: Progressive, painless loss of vision in the eye adjacent to the tumor; the optic disc appears pale and the visual field shows a central or peripheral defect.
• Contralateral papilledema: Swelling of the optic disc in the opposite eye, often with blurred margins, hemorrhages, and sometimes transient visual obscurations.
• Headache: Typically dull, worsening in the morning or with Valsalva maneuvers.
• Reduced sense of smell (hyposmia/anosmia): Frequently present when the lesion involves the olfactory groove.
• Facial numbness or weakness: If the tumor encroaches on cranial nerves III–VI.
• Nausea / vomiting: Related to increased ICP.
• Memory or personality changes: May occur with frontal‑lobe involvement.
• Double vision (diplopia): When extra‑ocular muscles are affected.

Because the visual loss can be subtle at first, many patients attribute the changes to “getting older” and delay seeking care.

Causes and Risk Factors

Foster Kennedy syndrome is not a disease itself; it is a clinical syndrome secondary to an underlying intracranial process.

Primary Causes

• Olfactory groove meningioma: The classic cause (≈ 70 % of reported cases).
• Other frontal‑lobe tumors: E.g., glioblastoma, astrocytoma, metastatic carcinoma.
• Benign cystic lesions: Arachnoid cysts or epidermoid cysts that expand in the frontal region.

Risk Factors for the Underlying Tumors

• Age > 30 years (most meningiomas appear after 40).
• Female sex for meningioma (estrogen‑mediated growth).
• Previous cranial radiation exposure.
• Genetic conditions such as neurofibromatosis type 2 (NF2) which predispose to meningiomas.
• Occupational exposure to ionizing radiation or certain chemicals (e.g., vinyl chloride).

Diagnosis

Diagnosis hinges on recognizing the asymmetric optic findings and confirming a space‑occupying lesion.

Clinical Examination

• Fundoscopy: Direct visualization of a pale optic disc (atrophic side) and a swollen disc with hyperemia (papilledema side).
• Visual acuity & visual field testing: Automated perimetry reveals a localized defect on the atrophic side and generalized field constriction on the papilledema side.
• Ophthalmic OCT (Optical Coherence Tomography): Quantifies retinal nerve fiber layer thinning on the atrophic side.

Neuro‑imaging

• MRI of the brain with contrast: Modality of choice; shows a well‑defined frontal‑lobe mass, often with a “dural tail” sign in meningioma.
• CT scan: Helpful if MRI is contraindicated; demonstrates hyperdense lesions and bone involvement.

Additional Tests

• Blood work: Baseline CBC, metabolic panel, and tumor markers if metastasis is suspected.
• Lumbar puncture: Rarely performed; may be needed if CSF analysis is required for atypical lesions.

Diagnostic Criteria (Simplified)

1. Unilateral optic atrophy + contralateral papilledema.
2. Evidence of a frontal‑lobe mass on imaging.
3. Exclusion of alternative causes (e.g., demyelinating disease, chronic hypertension).

Treatment Options

Treatment targets the underlying tumor and manages ICP. A multidisciplinary team—neurosurgeon, neuro‑ophthalmologist, radiation oncologist, and neurologist—is usually involved.

Surgical Management

• Craniotomy with tumor resection: First‑line for meningiomas; gross‑total removal is possible in > 80 % of cases when the tumor is accessible.
• Endoscopic endonasal approaches: Increasingly used for lesions near the skull base.

Radiation Therapy

• Fractionated external beam radiotherapy: For residual or unresectable tumor.
• Stereotactic radiosurgery (Gamma Knife, CyberKnife): Precise high‑dose treatment for small‑to‑medium lesions.

Medical Therapy

• Corticosteroids (e.g., dexamethasone): Reduce peritumoral edema and transiently improve papilledema.
• Anti‑epileptic drugs: If seizures occur.
• Hormonal therapy (e.g., tamoxifen): Rarely used for selected meningiomas expressing hormone receptors.

Supportive & Lifestyle Interventions

• Head elevation (30°) to aid venous drainage.
• Avoidance of activities that increase ICP (straining, heavy lifting).
• Regular ophthalmologic follow‑up to monitor visual fields.

Living with Foster Kennedy Syndrome

Even after successful tumor control, many patients experience lasting visual deficits. Practical strategies include:

• Low‑vision aids: Magnifiers, high‑contrast reading glasses, screen‑reading software.
• Vision therapy: Training to maximize the useful field of the remaining sight.
• Occupational therapy: Home modifications (bright lighting, decluttered pathways).
• Regular eye exams: At least annually, or sooner if vision changes.
• Psychological support: Counseling or support groups for coping with visual impairment.
• Medication adherence: Continue prescribed steroids or anti‑epileptics as directed.
• Healthy lifestyle: Balanced diet, regular aerobic exercise, and smoking cessation to lower risk of tumor recurrence.

Prevention

Because FKS is secondary to a tumor, primary prevention focuses on reducing risk factors for intracranial neoplasms:

• Limit exposure to ionizing radiation (e.g., avoid unnecessary CT scans).
• Use protective equipment when working with radiation or neuro‑toxic chemicals.
• Maintain optimal hormonal balance; discuss hormone replacement therapy risks with a physician.
• Screen and manage genetic conditions (e.g., NF2) through regular neuro‑imaging per specialist recommendations.

Complications

If left untreated, the underlying mass can cause:

• Permanent bilateral vision loss: Due to irreversible optic nerve damage.
• Severe intracranial hypertension: Leading to brain herniation, coma, or death.
• Seizures: From cortical irritation.
• Neurocognitive decline: Frontal‑lobe dysfunction affecting memory, judgment, and personality.
• Hydrocephalus: Obstructed CSF flow requiring shunting.

When to Seek Emergency Care

References

• Mayo Clinic. “Meningioma.” https://www.mayoclinic.org.
• Cleveland Clinic. “Papilledema and Optic Atrophy – Foster Kennedy Syndrome.” https://my.clevelandclinic.org.
• National Institutes of Health (NIH) – National Cancer Institute. “Meningioma Treatment (PDQ®)–Health Professional Version.” https://www.cancer.gov.
• World Health Organization. “WHO Classification of Tumours of the Central Nervous System, 5th edition.” 2021.
• J. A. Harris et al., “Foster Kennedy syndrome: Clinical features and outcome after surgical resection,” *Neurosurgery*, vol. 78, no. 4, 2016.

```